1988-P: Beyond Glycemic Control: Health-Related Quality-of-Life Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

Introduction and Objective: In type 2 diabetes mellitus (T2DM), health-related quality of life (HRQoL) is influenced by functional limitations and treatment effects beyond glycaemic control. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) provide cardiometabolic benefits that may translate into improved patient-reported outcomes. We evaluated HRQoL using the 36-Item Short Form Health Survey (SF-36) in adults with T2DM. Methods: SF-36 domain scores were calculated (n=122) for Physical Functioning (PF), Role-Physical (RP), Role-Emotional (RE), Vitality (VT), Mental Health (MH), Social Functioning (SF), Bodily Pain (BP), and General Health (GH). Norm-based Physical Component Summary (PCS) and Mental Component Summary (MCS) scores were derived. HRQoL profiles were descriptively compared by SGLT2i and GLP-1 RA use. Results: Marked impairment was observed in role-based domains, with lowest scores in RE (32.5 ± 41.6) and RP (41.5 ± 36.9). PF showed moderate limitation (58.8 ± 23.1), while VT (59.9 ± 19.9) and GH (61.8 ± 19.9) indicated reduced energy and fair perceived health. In contrast, MH (68.5 ± 18.2), SF (73.6 ± 21.9), and BP (71.3 ± 23.8) were relatively preserved. Norm-based analysis demonstrated substantial physical health impairment (PCS 40.8 ± 6.5) with lesser impact on mental health (MCS 44.9 ± 7.6). Patients receiving SGLT2i and/or GLP-1 RA demonstrated higher GH, VT, and BP scores and more favorable PCS compared with non-users, while differences in MCS were modest. Conclusion: In T2DM, SF-36 analysis highlights a dominant burden of physical and emotional role limitation. Use of SGLT2 inhibitors and GLP-1 receptor agonists is associated with improved physical health perception, vitality, and pain outcomes, supporting quality-of-life benefits beyond glycaemic control. Disclosure D.A. Padhye: None.